Interleukin-7 and immunorestoration in HIV: beyond the thymus.
One of the hallmarks of untreated HIV infection is a progressive loss of effective immunity to both HIV-associated and non-HIV antigens. Combination antiretroviral therapy can frequently control viral replication, resulting in variable levels of immune reconstitution, but has not resulted in restoration of effective immunity to the virus. Understanding the limitations of immune reconstitution following highly active antiretroviral therapy (HAART) and identifying approaches to enhance immunity in this context may not only improve outcome for patients with HIV infection but could also provide insight for immune reconstitution in other conditions associated with T cell depletion.
Fry
Terry J
TJ
Immunology Section, Pediatric Oncology Branch, Center for Cancer Research, National Institutes of Health, Bethesda, MD 20892-1928, USA. tf60y@nih.gov
Mackall
Crystal L
CL
D019380:Anti-HIV Agents / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active; D002454:Cell Differentiation; D015658:HIV Infections / Q000276:immunology* / Q000378:metabolism*; D006801:Humans; D015851:Interleukin-7 / Q000494:pharmacology*; D008954:Models, Biological; D013601:T-Lymphocytes / Q000276:immunology / Q000821:virology; D013950:Thymus Gland / Q000276:immunology
D019380:Anti-HIV Agents; D015851:Interleukin-7